Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 38

    1.

    Role of the anion exchanger 2 in the pathogenesis and treatment of primary biliary cirrhosis.

    Medina JF.

    Dig Dis. 2011;29(1):103-12. Epub 2011 Jun 17. Review.

    PMID:
    21691115
    [PubMed - indexed for MEDLINE]
    2.

    Treatment of primary biliary cirrhosis with ursodeoxycholic acid, budesonide and fibrates.

    Poupon R.

    Dig Dis. 2011;29(1):85-8. Epub 2011 Jun 17.

    PMID:
    21691111
    [PubMed - indexed for MEDLINE]
    3.

    Bile acid signaling in fetal tissues: implications for intrahepatic cholestasis of pregnancy.

    Williamson C, Miragoli M, Sheikh Abdul Kadir S, Abu-Hayyeh S, Papacleovoulou G, Geenes V, Gorelik J.

    Dig Dis. 2011;29(1):58-61. Epub 2011 Jun 17. Review.

    PMID:
    21691106
    [PubMed - indexed for MEDLINE]
    4.

    Pathophysiology of non-alcoholic steatohepatitis and basis for treatment.

    Pinzani M.

    Dig Dis. 2011;29(2):243-8. Epub 2011 Jul 5. Review.

    PMID:
    21734391
    [PubMed - indexed for MEDLINE]
    5.

    Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.

    Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M; HCC Expert Panel of Japan Society of Hepatology.

    Dig Dis. 2011;29(3):339-64. Epub 2011 Aug 9.

    PMID:
    21829027
    [PubMed - indexed for MEDLINE]
    6.

    Management of patients with hepatocellular carcinoma and extrahepatic metastasis.

    Lee HS.

    Dig Dis. 2011;29(3):333-8. Epub 2011 Aug 9. Review.

    PMID:
    21829026
    [PubMed - indexed for MEDLINE]
    7.

    Oral branched-chain amino acid granules reduce the incidence of hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis.

    Hayaishi S, Chung H, Kudo M, Ishikawa E, Takita M, Ueda T, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Ueshima K.

    Dig Dis. 2011;29(3):326-32. Epub 2011 Aug 9.

    PMID:
    21829025
    [PubMed - indexed for MEDLINE]
    8.

    Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma.

    Ueshima K, Kudo M, Takita M, Nagai T, Tatsumi C, Ueda T, Kitai S, Ishikawa E, Yada N, Inoue T, Hagiwara S, Minami Y, Chung H, Sakurai T.

    Dig Dis. 2011;29(3):321-5. Epub 2011 Aug 9.

    PMID:
    21829024
    [PubMed - indexed for MEDLINE]
    9.

    Future treatment option for hepatocellular carcinoma: a focus on brivanib.

    Kudo M.

    Dig Dis. 2011;29(3):316-20. Epub 2011 Aug 9. Review.

    PMID:
    21829023
    [PubMed - indexed for MEDLINE]
    10.

    mTOR inhibitor for the treatment of hepatocellular carcinoma.

    Kudo M.

    Dig Dis. 2011;29(3):310-5. Epub 2011 Aug 9. Review.

    PMID:
    21829022
    [PubMed - indexed for MEDLINE]
    11.

    Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.

    Kim HY, Park JW.

    Dig Dis. 2011;29(3):303-9. Epub 2011 Aug 9. Review.

    PMID:
    21829021
    [PubMed - indexed for MEDLINE]
    12.

    Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.

    Kudo M.

    Dig Dis. 2011;29(3):289-302. Epub 2011 Aug 9. Review.

    PMID:
    21829020
    [PubMed - indexed for MEDLINE]
    13.

    Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-β signaling in hepatocarcinogenesis.

    Yamazaki K, Masugi Y, Sakamoto M.

    Dig Dis. 2011;29(3):284-8. Epub 2011 Aug 9. Review.

    PMID:
    21829019
    [PubMed - indexed for MEDLINE]
    14.

    TGFBR3 polymorphisms and its haplotypes associated with chronic hepatitis B virus infection and age of hepatocellular carcinoma occurrence.

    Kim JH, Yu SJ, Park BL, Cheong HS, Pasaje CF, Bae JS, Lee HS, Shin HD, Kim YJ.

    Dig Dis. 2011;29(3):278-83. Epub 2011 Aug 9.

    PMID:
    21829018
    [PubMed - indexed for MEDLINE]
    15.

    Molecular targeted therapy for hepatocellular carcinoma: bench to bedside.

    Kudo M.

    Dig Dis. 2011;29(3):273-7. Epub 2011 Aug 9. Review.

    PMID:
    21829017
    [PubMed - indexed for MEDLINE]
    16.

    Role of the hepatic parenchyma in liver transplant tolerance: a paradigm revisited.

    Benseler V, Tay SS, Bowen DG, Bertolino P.

    Dig Dis. 2011;29(4):391-401. doi: 10.1159/000329802. Epub 2011 Aug 30. Review.

    PMID:
    21894010
    [PubMed - indexed for MEDLINE]
    17.

    Obesity and fatty liver are 'grease' for the machinery of hepatic fibrosis.

    Bosserhoff A, Hellerbrand C.

    Dig Dis. 2011;29(4):377-83. doi: 10.1159/000329800. Epub 2011 Aug 30. Review.

    PMID:
    21894008
    [PubMed - indexed for MEDLINE]
    18.

    ASH and NASH.

    Scaglioni F, Ciccia S, Marino M, Bedogni G, Bellentani S.

    Dig Dis. 2011;29(2):202-10. Epub 2011 Jul 5. Review.

    PMID:
    21734385
    [PubMed - indexed for MEDLINE]
    19.

    Ursodeoxycholic acid for treatment of fatty liver disease and dyslipidemia in morbidly obese patients.

    Marschall HU, Wagner M, Zollner G, Fickert P, Lackner C, Thorell A, Trauner M.

    Dig Dis. 2011;29(1):117-8. Epub 2011 Jun 17.

    PMID:
    21691117
    [PubMed - indexed for MEDLINE]
    20.

    Targeting nuclear bile acid receptors for liver disease.

    Trauner M, Baghdasaryan A, Claudel T, Fickert P, Halilbasic E, Moustafa T, Zollner G.

    Dig Dis. 2011;29(1):98-102. Epub 2011 Jun 17. Review.

    PMID:
    21691114
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk